阿尔茨海默病生物学与临床分期新标准的评估
该研究基于瑞典BioFINDER-2和ADNI队列,比较生物学与临床分期不一致的个体在共病理、共病和人口学特征上的差异。结果显示,临床分期比生物学分期更严重的个体更常伴有α-突触核蛋白病理、更高的NfL水平、更明显的TDP-43样萎缩和更多脑小血管病病变。
要点
- 临床分期比生物学分期更差的患者常存在非AD共病理。
- α-突触核蛋白病理、NfL升高和脑小血管病与症状严重度相关。
- 对临床损害超出生物学分期的AD患者应检测非AD生物标志物。
核心结论
- 共病理在tau缠结病理少于临床损害预期程度的个体中对症状严重度起重要作用。
研究设计与样本
- 研究纳入BioFINDER-2队列838例和ADNI队列380例淀粉样蛋白β阳性且接受tau-PET的参与者。
主要发现
- BioFINDER-2中37.7%生物学与临床分期一致,51.3%临床>生物学,11.0%生物学>临床。
- 临床>生物学组较参考组更常α-突触核蛋白病理阳性、NfL更高、TDP-43样萎缩更重、脑小血管病病变更重(FDR P<.05)。
- 生物学>临床组仅表现为神经变性更轻(皮质更厚;FDR P<.001)。
- ADNI队列重复主要结果:一致56.1%,临床>生物学36.1%,生物学>临床7.9%。
临床怎么用
- 对认知损害比生物学分期预期更重的AD患者,应评估非AD生物标志物以辅助诊断和预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: While clinical disease stages remained largely unchanged in the 2024 update of the Alzheimer disease (AD) criteria, tau-positron emission tomography (PET) was introduced as a core biomarker and its spatial extent was incorporated into the revised biological stages of the disease. It is important to consider both the clinical and the biological stages and understand their discrepancies. OBJECTIVE: To compare individuals who have discrepant biological and clinical stages with those who have congruent stages in terms of copathologies, comorbidities, and demographics. DESIGN, SETTING, AND PARTICIPANTS: Participants were from the Swedish BioFINDER-2 (inclusion from 2017 through 2023) and the Alzheimer's Disease Neuroimaging Initiative (ADNI) (inclusion from 2015 through 2024). BioFINDER-2 included a prospective population-based (cognitively normal [CN] older adults) and memory clinic-based cohort (participants with subjective cognitive impairment [SCD], mild cognitive impairment [MCI], and dementia). ADNI included a volunteer-based sample. All participants who were amyloid-β positive and had undergone tau-PET were included. In BioFINDER-2, 838 participants of a total of 1979 were included, and of 927 with tau-PET in ADNI, 380 were included. EXPOSURES: The clinical (CN to dementia) and biological (based on PET; initial [amyloid-β-positive only] to advanced [amyloid-β-positive, elevated, and widespread tau]) stages from the revised AD criteria. MAIN OUTCOMES AND MEASURES: Cross-sectional measures of neurodegeneration (cortical thickness, TAR DNA-binding protein 43 [TDP-43] imaging signature, neurofilament light [NfL]), α-synuclein cerebrospinal fluid status, plasma glial fibrillary acidic protein, white matter lesions, infarcts, microbleeds, comorbidities, and demographics. RESULTS: There were 838 BioFINDER-2 participants (mean age, 73.9 [SD, 7.3] years; 431 women [51%]; 407 men [49%]) and 380 ADNI participants (average age, 72.9 [SD, 7.0] years; 194 women [51%]; 186 mean [49%]) included. In BioFINDER-2, 37.7% of the sample had congruent biological and clinical stages (reference group), 51.3% had more advanced clinical impairment compared with their clinical stage (clinical > biological) and 11.0% had the opposite (biological > clinical). The main differences were between the reference group and the clinical > biological group: the latter participants were more often positive for α-synuclein pathology, had higher NfL levels, greater TDP-43-like atrophy, and higher burden of cerebral small vessel disease lesions (all false discovery rate P < .05). The only difference between the biological > clinical and the reference group was that the former had less neurodegeneration (thicker cortex; all false discovery rate P < .001). The main results were replicated in the independent ADNI cohort, where congruent 56.1% of participants had biological and clinical stages; 36.1% were in the category clinical > biological, and 7.9% in biological > clinical. CONCLUSIONS AND RELEVANCE: Copathologies play an important role in symptom severity in individuals who harbor less tau-tangle pathology than expected for their clinical impairment. These results highlight the importance of measuring non-AD biomarkers in patients with AD with worse cognitive impairment than expected based on their biological stage, which could impact the clinical diagnosis and prognosis.
引用
- Pichet Binette A, Smith R, Salvadó G, et al. Evaluation of the Revised Criteria for Biological and Clinical Staging of Alzheimer Disease. JAMA Neurol. 2025. PMID: 40388185. doi:10.1001/jamaneurol.2025.1100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。